But neladalkib results worsen, and come with a red flag about liver enzyme elevations.
ApexOnco Front Page
Recent articles
The private biotech adds another asset to J&J’s prostate cancer pipeline.
Pumitamig is the latest to be tested in first-line disease.
China's Harmoni-A trial hits on overall survival, but hopes for a global phase 3 seem optimistic.
Qilu moves its GPRC5D T-cell engager into phase 3, but trispecifics set the new pace.
Meanwhile, Royalty Pharma stakes $885m on $2.8bn sales by 2035.
After Dren secured buy-in from Novartis, LTZ becomes a clinical player.
New draft guidance could see the agency getting ever stricter.
